Evidence map›Paper›PMID 38623902›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024

Maurice Pasternak, Saira S Mirza, Nicholas Luciw, Henri J M M Mutsaerts, Jan Petr, David Thomas, David Cash, Martina Bocchetta, Maria Carmela Tartaglia, Sara B Mitchell and 33 more

Open access · hybridAbstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Targeting Arterial Dysfunction in Cardiovascular Disease Using Stem Cell-Based Therapies.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

43 authors at 20 institutions in 9 countries.

Maurice PasternakHurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.ORCID 0000-0003-0647-172X
Saira S MirzaHurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
Nicholas LuciwHurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
Henri J M M MutsaertsDepartment of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Jan PetrHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
David ThomasDepartment of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, Queen Square, London, UK.
David CashDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, UK.
Martina BocchettaDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, UK.
Maria Carmela TartagliaTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
Sara B MitchellDivision of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Sandra E BlackDivision of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Morris FreedmanDivision of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
David Tang-WaiDivision of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Ekaterina RogaevaTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
Lucy L RussellDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, UK.
Arabella BouziguesDepartment of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, Queen Square, London, UK.
John C van SwietenDepartment of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands.
Lize C JiskootDepartment of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands.
Harro SeelaarDepartment of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands.
Robert LaforceClinique Interdisciplinaire de Mémoire, CHU de Québec, Département des Sciences Neurologiques, Université Laval, Quebec, Quebec, Canada.
Pietro TiraboschiDivision of Neurology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Barbara BorroniDepartment of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Daniela GalimbertiDepartment of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
James B RoweDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Caroline GraffDepartment of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden.
Elizabeth FingerDepartment of Clinical Neurological Sciences, Western University, London, Ontario, Canada.
Sandro SorbiDepartment of Neurofarba, University of Florence, Florence, Italy.
Alexandre de MendonçaNeurology Department, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.
Chris ButlerNuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK.
Alex GerhardDivision of Psychology Communication and Human Neuroscience, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK.
Raquel Sanchez-ValleAlzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clinic de Barcelona, Barcelona, Spain.
Fermin MorenoCognitive Disorders Unit, Department of Neurology, Donostia University Hospital Gipuzkoa Building, Begiristain Doktorea Pasealekua, Donostia-San Sebastian, Gipuzkoa, Spain.
Matthis SynofzikDepartment of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.
Rik VandenbergheLaboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.
Simon DucharmeDepartment of Psychiatry, Douglas Mental Health University Institute, McGill University, Montreal, Quebec, Canada.
Johannes LevinDepartment of Neurology, Ludwig-Maximilians-University, Munich, Germany.
Markus OttoDepartment of Neurology, University of Ulm, Ulm, Germany.
Isabel SantanaCenter for Neuroscience and Cell Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
Antonio P StrafellaKrembil Research Institute, University Health Network, Toronto, Ontario, Canada.
Bradley J MacIntoshHurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
Jonathan D RohrerDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, UK.
Mario MasellisHurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
GENetic Frontotemporal dementia Initiative (GENFI)
Sunnybrook Health Science Centre · CANIHR Queen Square Dementia Biomedical Research Unit · GBErasmus MC · NLNational Hospital for Neurology and Neurosurgery · GBAmsterdam Neuroscience · NLBiogipuzkoa Health Research Institute · ESDon Carlo Gnocchi Foundation · ITFondazione IRCCS Istituto Neurologico Carlo Besta · ITHelmholtz-Zentrum Dresden-Rossendorf · DEHertie Institute for Clinical Brain Research · DEHospital Clínic de Barcelona · ESKarolinska University Hospital · SEKU Leuven · BEMontreal Neurological Institute and Hospital · CAMRC Cognition and Brain Sciences Unit · GBMunich Cluster for Systems Neurology · DEUniversität Ulm · DEUniversité Laval · CAUniversity Health Network · CAUniversity of Brescia · IT

Funding

Canada International Scientific Exchange ProgramCIHR MOP-327387CIHR PJT-175242Deutsche ForschungsgemeinschaftEU Joint Programme Neurodegenerative Disease Research-GENFI-PROXEU Joint Programme Neurodegenerative Disease Research Prefrontals Vetenskapsrådet Dnr 529-2014-7504European UnionInstituto de Salud Carlos III 20/0448Joseph Bazylewicz FellowshipsJPND GENFI-PROX DLR/BMBF 2019- 02248Medical Research Council MC_UU_00030/14Medical Research Council MR/T033371/1Medical Research Council UK MR/M023664/1Morris Kerzner Memorial FundMRC Clinician Scientist Fellowship MR/M008525/1Munich Cluster for Systems Neurology EXC 2145 SyNergy - ID 390857198National Institute for Health Research Cambridge Biomedical Research Centre NIHR203312NIHR Rare Disease Translational Research Collaboration BRC149/NS/MHSaul A. Silverman Family FoundationSwedish FTD Initiative Schörling FoundationUniversity of Toronto Medical Science OpenVetenskapsrådet 2015-02926Vetenskapsrådet 2018-02754Vetenskapsrådet 2019-0224Weston Brain InstituteZonMW Memorabel 733 051 042
6 · The paper itself

Abstract

introductionEffective longitudinal biomarkers that track disease progression are needed to characterize the presymptomatic phase of genetic frontotemporal dementia (FTD). We investigate the utility of cerebral perfusion as one such biomarker in presymptomatic FTD mutation carriers.

methodsWe investigated longitudinal profiles of cerebral perfusion using arterial spin labeling magnetic resonance imaging in 42 C9orf72, 70 GRN, and 31 MAPT presymptomatic carriers and 158 non-carrier controls. Linear mixed effects models assessed perfusion up to 5 years after baseline assessment.

resultsPerfusion decline was evident in all three presymptomatic groups in global gray matter. Each group also featured its own regional pattern of hypoperfusion over time, with the left thalamus common to all groups. Frontal lobe regions featured lower perfusion in those who symptomatically converted versus asymptomatic carriers past their expected age of disease onset. DISCUSSION: Cerebral perfusion is a potential biomarker for assessing genetic FTD and its genetic subgroups prior to symptom onset. HIGHLIGHTS: Gray matter perfusion declines in at-risk genetic frontotemporal dementia (FTD). Regional perfusion decline differs between at-risk genetic FTD subgroups . Hypoperfusion in the left thalamus is common across all presymptomatic groups. Converters exhibit greater right frontal hypoperfusion than non-converters past their expected conversion date. Cerebral hypoperfusion is a potential early biomarker of genetic FTD.

Indexed as

C9orf72 ProteinCerebrovascular CirculationFrontotemporal DementiaMagnetic Resonance Imagingtau ProteinsAdultAgedBiomarkersBrainDisease ProgressionFemaleGray MatterHeterozygoteHumansLongitudinal StudiesMaleBiomarkersC9orf72 ProteinProgranulinsSpin Labelstau Proteinsarterial spin labelingcerebral perfusionfrontotemporal dementiapresymptomatic biomarker

Identifiers

PMID38623902
PMCPMC11095434
OpenAlexW4394845710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.